Ashton Thomas Private Wealth, LLC
Position in DGX — Quest Diagnostics Inc
CIK 2019663
SCOTTSDALE, AZ
Position in DGX
as of Jun 30, 2026
· filed Jul 29, 2026
Position Value
$1,982,368
+$146,036 QoQ
Shares Held
9,353
-0.2% QoQ
Ownership
0.008%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
#386
of 1,090 holders
Holding Since
Mar 2020
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DGX Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026Ashton Thomas Private Wealth, LLC holds $12,239,667 across 8 Diagnostics & Research names. DGX ranks #2 (16.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TMO |
Thermo Fisher Scientific Inc.
|
12,543 | $6,288,558 | |
| 2 | DGX |
Quest Diagnostics Inc
This page
|
9,353 | $1,982,368 | |
| 3 | DHR |
Danaher Corp /De/
|
6,669 | $1,270,311 | |
| 4 | LH |
Labcorp Holdings Inc.
|
2,877 | $805,560 | |
| 5 | A |
Agilent Technologies, Inc.
|
5,221 | $693,505 | |
| 6 | CDNA |
CareDx, Inc.
|
16,502 | $470,307 | |
| 7 | IQV |
Iqvia Holdings Inc.
|
2,242 | $433,199 | |
| 8 | IDXX |
Idexx Laboratories Inc /De
|
562 | $295,859 |
All Filings in DGX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,982,368 | 9,353 | Shares | Sole | 2026-07-29 | |
| 2026-03-31 | $1,836,332 | 9,370 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $1,555,522 | 8,964 | Shares | Sole | 2026-01-29 | |
| 2025-09-30 | $1,618,214 | 8,491 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $1,229,387 | 6,844 | Shares | Sole | 2025-08-01 | |
| 2025-03-31 | $771,382 | 4,559 | Shares | Sole | 2025-05-16 | |
| 2024-12-31 | $629,991 | 4,176 | Shares | Sole | 2025-02-07 | |
| 2024-06-30 | $15,193 | 111 | Shares | Sole | 2024-08-07 | |
| 2020-03-31 | $799,065 | 9,951 | Shares | Sole | 2024-04-22 | |
| No filing history on record for this holder in this stock. | ||||||